Article Details
Retrieved on: 2022-09-09 08:20:39
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Meanwhile, all the drugs for AMD and DME are expected to be squeezed by lower-cost, biosimilar versions of Novartis and Roche's Lucentis (ranibizumab) ...
Article found on: pharmaphorum.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here